CorMedix Inc. (CRMD)
- Previous Close
5.42 - Open
5.50 - Bid 5.25 x 600
- Ask 5.29 x 300
- Day's Range
5.13 - 6.22 - 52 Week Range
2.57 - 7.00 - Volume
1,949,116 - Avg. Volume
564,062 - Market Cap (intraday)
290.3M - Beta (5Y Monthly) 1.89
- PE Ratio (TTM)
-- - EPS (TTM)
-0.91 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.00
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
www.cormedix.comRecent News: CRMD
Performance Overview: CRMD
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRMD
Valuation Measures
Market Cap
298.00M
Enterprise Value
222.63M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
4.25
Enterprise Value/Revenue
3.79k
Enterprise Value/EBITDA
-4.82
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.47%
Return on Equity (ttm)
-74.02%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-46.34M
Diluted EPS (ttm)
-0.91
Balance Sheet and Cash Flow
Total Cash (mrq)
76.03M
Total Debt/Equity (mrq)
0.95%
Levered Free Cash Flow (ttm)
-22.97M
Research Analysis: CRMD
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell